Difficulties in the treatment of intestinal amoebiasis in mentally disabled individuals at a rehabilitation institution for the intellectually impaired in Japan

Chemotherapy

Volumn 56, Issue 4, 2010, Pages 348-352

  Fujishima, Tsukasa ^a   Nishise, Shoichi ^b   Ichihara, Masahiro ^a   Kobayashi, Seiki ^c   Takeuchi, Tsutomu ^c  

^a Shirataka Town Hospital   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

^c KEIO UNIVERSITY   (Japan)

Author keywords

Diloxanide furoate; Entamoeba histolytica; Luminal drug; Mass infection; Metronidazole; Recurring infection

Indexed keywords

DILOXANIDE FUROATE; METRONIDAZOLE;

AMEBIASIS; ANTIGEN DETECTION; ARTICLE; COPROPHAGY; DRUG EFFECT; ENTAMOEBA HISTOLYTICA; FECES ANALYSIS; FEMALE; HUMAN; INTELLECTUAL IMPAIRMENT; INTESTINE AMEBIASIS; JAPAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; NONHUMAN; PRIORITY JOURNAL; RECURRENT INFECTION; SEROLOGY; TREATMENT RESPONSE;

AMEBICIDES; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; DYSENTERY, AMEBIC; ENTAMOEBA HISTOLYTICA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; FURANS; HUMANS; JAPAN; MALE; MENTALLY DISABLED PERSONS; METRONIDAZOLE; REHABILITATION CENTERS; TREATMENT OUTCOME;

EID: 77955634457     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320187     Document Type: Article

References (14)

1. Nozaki T, Kobayashi S, Takeuchi T, Haghighi A: Diversity of clinical isolates of Entamoeba histolytica in Japan. Arch Med Res 2006; 37: 277-279.
2. Infectious Disease Surveillance Center: IDWR surveillance data table. Page 1: notifiable diseases. 2009. http://idsc.nih.go.jp/ idwr/ydata/report-Ja. html.
3. Haghighi A, Kobayashi S, Takeuchi T, Thammapalerd N, Nozaki T: Geographic diversity among genotypes of Entamoeba histolytica field isolates. J Clin Microbiol 2003; 41: 3748-3756.
4. Flagyl tabs package insert, rev 7/90, rec 9/93. Searle, USA.
5. Blessmann J, Tannich E: Treatment of asymptomatic intestinal Entamoeba histolytica infection. N Engl J Med 2002; 347: 1384.
6. McAuley JB, Herwaldt BL, Stokes SL, Becher JA, Roberts JM, Michelson MK, Juranek DD: Diloxanide furoate for treating asymptomatic Entamoeba histolytica cyst passers: 14 years' experience in the United States. Clin Infect Dis 1992; 15: 464-468.
7. Ritchie LS: An ether sedimentation technique for routine stool examinations. Bull US Army Med Dept 1948; 8: 326.
8. Robinson GL: The laboratory diagnosis of human parasitic amoebae. Trans R Soc Trop Med Hyg 1968; 62: 285-294.
9. Sargeaunt PG: Zymodemes of Entamoeba histolytica; in Radvin JI (ed): Amoebiasis: Human Infection by Entamoeba histolytica . New York, John Wiley & Sons, 1988, pp 370- 387.
10. Tachibana H, Kobayashi S, Takekoshi M, Ihara S: Distinguishing pathogenic isolates of Entamoeba histolytica by polymerase chain reaction. J Infect Dis 1991; 164: 825-826.
11. Takeuchi T, Matsuda H, Okuzawa E, Nozaki T, Kobayashi S, Tanaka H: Application of a micro enzyme-linked immunosorbent assay (ELISA) to detection of anti-amebic antibody in various forms of amebic infection. Jpn J Exp Med 1988; 58: 229-232.
12. Pal D, Banerjee S, Cui J, Schwartz A, Ghosh SK, Samuelson J: Giardia , Entamoeba , and Trichomonas enzymes activate metronidazole (nitroreductases) and inactivate metronidazole (nitroimidazole reductases). Antimicrob Agents Chemother 2009; 53: 458-464.
13. Lee CC, Lee VW, Chan FK, Ling TK: Levofloxacin- resistant Helicobacter pylori in Hong Kong. Chemotherapy 2008; 54: 50-53.
14. Soto A, Garcia A, Gonzalez CL: In vitro antagonism of rabeprazole and metronidazole upon clinical isolates of Helicobacter pylori . Chemotherapy 2009; 55: 308-311.